Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2015. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure regarding executive compensation rather than a financial results report.
Material Changes and Transactions
The primary event disclosed is the grant of a conditional share award to Emma Walmsley on August 4, 2015, under the 2009 Performance Share Plan (PSP). Key details include:
- Recipient: Emma Walmsley (PDMR).
- Award Size: 59,493 Ordinary Shares.
- Context: The award recognizes Ms. Walmsley's increased role and responsibility as CEO of the new joint venture, GSK Consumer Healthcare, following the completion of a three-way transaction with Novartis.
- Share Price: The closing price of an Ordinary Share on the grant date was £14.01.
Guidance, Outlook, and Conditions
The filing outlines the terms of the conditional award rather than providing corporate guidance or outlook. The vesting of the award is dependent on the achievement of three equally weighted performance measures set by the Remuneration Committee. Dividends will accrue during the three-year performance period but will only vest if the underlying awards vest. The specific performance targets were detailed in company announcements dated February 12 and July 31, 2015.
Investor Verification Checklist
- Verify the specific performance targets for the 2009 PSP referenced in the February 12 and July 31, 2015 announcements.
- Confirm the final vesting percentage once the three-year performance period concludes.
- Review the broader implications of the Novartis transaction on GSK Consumer Healthcare leadership structure.